SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review

Nisha S Mehta1, Oliver T Mytton2, Edward W S Mullins3,4

  • 1Department of Health and Social Care (England), London, United Kingdom.

Insights

Children show a low observed case rate for coronavirus disease 2019 (COVID-19), but infection susceptibility may be similar to adults. This suggests many pediatric COVID-19 cases are asymptomatic or mild, impacting observed data.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Epidemiology

Background:

  • Limited understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemiology in children.
  • Need to clarify infection rates, clinical presentation, and outcomes in pediatric COVID-19 cases.

Purpose of the Study:

  • To systematically review and synthesize existing literature on SARS-CoV-2 in pediatric populations.
  • To inform clinical and public health strategies for managing pediatric COVID-19.

Main Methods:

  • Rapid systematic review and narrative synthesis of published literature.
  • Searched multiple databases and COVID-19 resource centers, including studies on SARS-CoV and MERS-CoV.
  • Included English abstracts of Chinese-language papers.

Main Results:

  • Twenty-four studies on COVID-19 in children were reviewed.
  • Children exhibit a lower observed case rate but similar susceptibility to SARS-CoV-2 infection compared to adults.
  • Pediatric cases often present as asymptomatic or mild, with scarce data on severe outcomes and transmission.

Conclusions:

  • A discrepancy exists between low observed pediatric COVID-19 case rates and potentially similar infection rates to adults.
  • Mild or asymptomatic infections in children may lead to undercounting in observed COVID-19 cases.
  • Further research is needed to fully understand pediatric SARS-CoV-2 transmission and clinical outcomes.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
190
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
169
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
172
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K